In a double-blind trial, 12 patients with probable Alzheimer's disease
were treated for 6 weeks with placebo and 6 weeks with monosialoganglioside
(GM1) (100 mg/day i.m.), which potentiates the actions of nerve growth
factor. GM1 failed to produce significant improvement in patients'
cognitive test performance, suggesting that this is not a viable approach
to the treatment of cognitive deterioration in Alzheimer's disease.